vTv Therapeutics Inc. (NASDAQ:VTVT – Get Rating) – Investment analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of vTv Therapeutics in a report issued on Monday, June 6th. Cantor Fitzgerald analyst C. Duncan expects that the biotechnology company will post earnings per share of ($0.33) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock.

Other research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Wednesday, May 18th. StockNews.com started coverage on shares of vTv Therapeutics in a report on Monday. They issued a “sell” rating on the stock.

vTv Therapeutics stock opened at $0.68 on Thursday. The firm’s 50-day moving average is $0.61 and its 200-day moving average is $0.79. vTv Therapeutics has a 1 year low of $0.38 and a 1 year high of $2.88.

vTv Therapeutics (NASDAQ:VTVT – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.00 million.

Several hedge funds have recently added to or reduced their stakes in VTVT. Morgan Stanley increased its holdings in shares of vTv Therapeutics by 1,575.3% in the 2nd quarter. Morgan Stanley now owns 36,756 shares of the biotechnology company’s stock worth $83,000 after acquiring an additional 34,562 shares during the period. Geode Capital Management LLC increased its stake in vTv Therapeutics by 77.2% during the 3rd quarter. Geode Capital Management LLC now owns 347,635 shares of the biotechnology company’s stock valued at $531,000 after buying an additional 151,435 shares during the period. GSA Capital Partners LLP acquired a new position in vTv Therapeutics during the 3rd quarter valued at about $177,000. Two Sigma Securities LLC acquired a new position in vTv Therapeutics during the 3rd quarter valued at about $26,000. Finally, Cim Investment Management Inc. increased its stake in vTv Therapeutics by 100.0% during the 4th quarter. Cim Investment Management Inc. now owns 354,746 shares of the biotechnology company’s stock valued at $447,000 after buying an additional 177,373 shares during the period. 7.35% of the stock is currently owned by institutional investors and hedge funds.

About vTv Therapeutics (Get Rating)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

See Also

Receive News & Ratings for vTv Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for vTv Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.